Themis Medicare Limited (IN:THEMISMED)
:THEMISMED
Want to see IN:THEMISMED full AI Analyst Report?
Top Page
Themis Medicare Limited
(THEMISMED)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹112.00
▲(9.27% Upside)
Action:Reiterated
Date:05/31/26
The score is held back primarily by weak financial performance, driven by steep margin compression and a shift to negative operating and free cash flow, despite manageable leverage. Technicals are a key offset, with the stock trading above major moving averages and showing positive momentum. Valuation is middling due to a negative P/E and only a small dividend yield.
Positive Factors
Manageable leverage
Low debt relative to equity gives the company financial flexibility to withstand continued margin pressure and fund working capital or strategic investments without heavy interest burden. This balance sheet cushion supports durability while management works to restore profitability.
Negative Factors
Sharp margin deterioration
A large, rapid collapse in gross margin signals structural pressure from pricing, cost inflation, or an adverse product mix. Sustained lower gross margins erode operating leverage, make profitability recovery harder, and reduce the firm's ability to self-fund investments or absorb shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
Low debt relative to equity gives the company financial flexibility to withstand continued margin pressure and fund working capital or strategic investments without heavy interest burden. This balance sheet cushion supports durability while management works to restore profitability.
Read all positive factors
Themis Medicare Limited (THEMISMED) vs. iShares MSCI India ETF (INDA)
Market Cap
₹9.39B
Dividend Yield0.48%
Average Volume (3M)6.87K
Price to Earnings (P/E)823.8
Beta (1Y)1.53
Revenue Growth-15.60%
EPS Growth-96.35%
CountryIN
Employees1,509
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.92
Shares Outstanding92,100,120
10 Day Avg. Volume6,301
30 Day Avg. Volume6,868
Financial Highlights & Ratios
PEG Ratio-5.72
Price to Book (P/B)1.58
Price to Sales (P/S)1.84
P/FCF Ratio-37.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Themis Medicare Limited Business Overview & Revenue Model
Company Description
Themis Medicare Limited, along with its affiliated entities, is a pharmaceutical company that produces and supplies medicinal goods for both the Indian and international markets. Its product portfolio encompasses active pharmaceutical ingredients ...
How the Company Makes Money
The company primarily makes money by selling pharmaceutical products. Its key revenue streams include (1) sales of finished formulations (finished dosage medicines) to customers in India and/or overseas markets and (2) sales of active pharmaceutic...
Themis Medicare Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
66
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.41B | 3.42B | 4.06B | 3.82B | 3.54B | 3.95B |
| Gross Profit | 2.15B | 1.09B | 2.74B | 2.42B | 2.36B | 2.43B |
| EBITDA | -99.69M | 3.93M | 490.48M | 733.17M | 789.56M | 1.02B |
| Net Income | -269.80M | 11.44M | 298.33M | 435.24M | 569.01M | 728.81M |
Balance Sheet | ||||||
| Total Assets | 5.82B | 5.98B | 5.88B | 5.66B | 5.14B | 4.28B |
| Cash, Cash Equivalents and Short-Term Investments | 189.59M | 91.50M | 65.59M | 99.22M | 125.47M | 202.79M |
| Total Debt | 955.64M | 1.00B | 829.88M | 957.92M | 923.75M | 797.32M |
| Total Liabilities | 2.02B | 1.99B | 1.85B | 1.89B | 1.75B | 1.40B |
| Stockholders Equity | 3.80B | 3.99B | 4.03B | 3.78B | 3.39B | 2.87B |
Cash Flow | ||||||
| Free Cash Flow | -40.38M | -167.31M | 192.84M | 36.76M | -126.55M | 137.67M |
| Operating Cash Flow | -14.84M | -118.60M | 347.10M | 220.94M | 160.93M | 343.94M |
| Investing Cash Flow | -6.82M | -45.09M | -121.74M | -159.48M | -239.62M | -155.86M |
| Financing Cash Flow | 37.41M | 126.83M | -258.98M | -87.70M | 1.36M | -175.47M |
Themis Medicare Limited Technical Analysis
Neutral
102.50
Price Trends
98.34
Positive
89.97
Positive
101.47
Positive
Market Momentum
1.06
Positive
50.18
Neutral
27.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THEMISMED, the sentiment is Neutral. The current price of 102.5 is below the 20-day moving average (MA) of 104.59, above the 50-day MA of 98.34, and above the 200-day MA of 101.47, indicating a neutral trend. The MACD of 1.06 indicates Positive momentum. The RSI at 50.18 is Neutral, neither overbought nor oversold. The STOCH value of 27.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:THEMISMED.
Themis Medicare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹14.26B | 34.26 | ― | 1.24% | 6.89% | -23.34% | |
74 Outperform | ₹23.52B | 22.61 | ― | ― | 17.97% | 126.79% | |
60 Neutral | ₹6.40B | 96.06 | ― | ― | -1.22% | -52.32% | |
58 Neutral | ₹16.26B | 34.01 | ― | ― | 226.01% | -84.17% | |
57 Neutral | ₹9.31B | 11.82 | ― | ― | 8.79% | 120.02% | |
53 Neutral | ₹9.39B | 823.78 | ― | 0.48% | -15.60% | -96.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:THEMISMED
Themis Medicare Limited
102.00
-30.01
-22.73%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
187.25
82.34
78.49%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
212.35
-2.67
-1.24%
IN:VENUSREM
Venus Remedies Limited
1,759.40
1,330.25
309.97%
IN:WANBURY
Wanbury Limited
266.60
-1.95
-0.73%
IN:ZIMLAB
Zim Laboratories Ltd.
119.45
9.07
8.22%
Themis Medicare Limited Corporate Events
Themis Medicare Receives SEBI Dematerialisation Compliance Certificate for March Quarter
Apr 8, 2026
Themis Medicare Limited has disclosed that it received a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2026. The certificate, issued by its registrar and ...
Themis Medicare Shareholders Approve Resolutions via Postal Ballot
Mar 28, 2026
Themis Medicare Limited has announced the completion of a postal ballot process, conducted through remote e-voting, to seek shareholder approval on various business resolutions. The company reported that all resolutions detailed in the February 25...
Themis Medicare contests Rs 13.32 crore income-tax demand, says no hit to finances
Mar 26, 2026
Themis Medicare Limited has disclosed that it received a notice from the Income Tax Department’s Vapi circle under Section 226(3) of the Income-tax Act, directing payment of outstanding tax demands for assessment years 2017-18, 2018-19 and 2...
Themis Medicare Closes Trading Window Ahead of March Quarter Results
Mar 24, 2026
Themis Medicare Limited has announced the closure of its trading window for dealings in the company’s shares from 1 April 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and its own code of conduct. The window will...
Themis Medicare Raises Price for Preferential Convertible Warrants to Institutional Investor
Mar 10, 2026
Themis Medicare Limited has revised the pricing of its proposed convertible equity warrants to Rs. 102.87 per warrant, up from an earlier Rs. 100, following a modified pricing certificate issued under SEBI regulations. The warrants, to be issued v...
Themis Medicare Raises Price, Amends Terms of Promoters’ Preferential Warrant Issue
Mar 10, 2026
Themis Medicare has issued a corrigendum to its February 25, 2026 postal ballot notice seeking shareholder approval for a preferential issue of convertible equity warrants to promoter group entity Vividhmargi Investments. Following observations fr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.